Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat | Nasdaq
Leap reverse merges, secures $30M for I/O antibodies | Fierce Biotech
PUMA Biotechnology, Inc. Form S-1
Puma Biotechnology
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI) | Nasdaq
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
Gordon Esplin - Chief Accounting Officer - Puma Biotechnology, Inc. | LinkedIn
Finance Watch: Biopharma IPO Market Silence Continues In The US :: Scrip
Institutional investors own a significant stake of 45% in Puma Biotechnology, Inc. (NASDAQ:PBYI)
The 10 Annual BIO Investor Forum – Program Business Roundtable Therapeutic Workshop
From Public To Private, Crossover Investors Are Back In Biotech :: Scrip
Alan H. Auerbach - Chief Executive Officer & President @ Puma Biotechnology - Crunchbase Person Profile
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
DEFA14A
Puma Biotechnology, Inc. | LinkedIn
Choice newcomers piggyback on 2012's IPO successes | Evaluate
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
PBYI: Puma Biotechnology Inc Stock Price Quote - NASDAQ GS - Bloomberg
Puma Biotechnology, Inc. | LinkedIn
PBYI Institutional Ownership and Shareholders - Puma Biotechnology Inc (NASDAQ) Stock
From summer lull to biotech's record-breaking month | Evaluate
